ADXN vs AIM

Addex Therapeutics Ltd vs AIM ImmunoTech Inc. — Valuation Comparison 2026

ADXN

Biotechnology
Addex Therapeutics Ltd
Quality
5.5
out of 10
Value Trap
20
SAFE
Price
$6.82
Last close
Models
6/13
Active
VS

AIM

Biotechnology
AIM ImmunoTech Inc.
Quality
4.2
out of 10
Value Trap
32
LOW
Price
$0.44
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType ADXN Fair ValueADXN Upside AIM Fair ValueAIM Upside
Bayesian DCF Intrinsic $0.14 -66.9%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $13.22 +88.8% $0.02 -95.5%
Dynamic NAV Asset-Based $6.04 -11.4% $1.51 +245.6%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ADXN vs AIM — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ADXN vs AIM — Which Stock Is More Undervalued?

ADXN scores higher with a 5.5/10 quality rating vs AIM's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Addex Therapeutics Ltd (ADXN) and AIM ImmunoTech Inc. (AIM) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ADXN currently trades at $6.82 with a QOC of 5.5/10, while AIM trades at $0.44 with a QOC of 4.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).